These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28656792)

  • 1. Recent advances in targeted advanced lung cancer therapy in the elderly.
    Losanno T; Gridelli C
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):787-797. PubMed ID: 28656792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer.
    Zaarour M; Nazha B; Weerasinghe C; Moussaly E; Terjanian T
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):877-83. PubMed ID: 27328177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W; Tufman A; Huber RM
    Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
    Meoni G; Cecere FL; Lucherini E; Di Costanzo F
    J Geriatr Oncol; 2013 Jul; 4(3):282-90. PubMed ID: 24070465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage P
    Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.
    Zaarour M; Weerasinghe C; Nazha B; Hassan S; Atallah JP
    Expert Rev Anticancer Ther; 2015; 15(11):1327-36. PubMed ID: 26414352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
    Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.